NCT Number: NCT01989819
Primary Sjögren Syndrome
Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems. Fifteen to twenty percent of patients with the primary Sjögren's syndrome have neurological complications involving the peripheral nervous system. Although some patients have large fiber neuropathy, around forty percent of patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms, some have been shown to have small fiber neuropathy (SFN). A recent study proved that more than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.
The aim of this study will be to investigate the occurrence of small fiber neuropathy in patients with pSS and neuropathic pain with normal electromyographic studies and to determine the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is a valuable tool to diagnose small fiber neuropathy and the method has been widely validated. A skin biopsy will be performed in patients and control and will allow quantification of small fiber density in skin sample along with measurement of sweat gland innervation. Moreover, pathophysiological studies will be carried on in order to evaluate the causal relationship between cellular and humoral inflammation and small fiberneuropathy.
Recent studies have pointed out the inconstant efficacy of both corticosteroid and immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small fiber neuropathy in these patients may help designing new therapeutic strategies.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
CH d'Albi, Albi, France
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with pSS according to revised European criteria and exhibiting neuropathic pain without any electromyographic abnormality will be included (Group I).
- Age of entry into the study ≥ 18 yrs (both groups).
- Affiliated or profit patient of a social security system (both groups).
- Informed consent signed up (both groups).
Exclusion criteria
- Chronic alcoholism
- Type I or type II diabetes
- Peripheral neuropathy unrelated to pSS complications
- Coagulation disease
- Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil
- Porphyria, methemoglobinemia
- Patients under measure of maintenance of justice.
- Patients unable to understand or to participate to the study.
- Child and major patients making the object of a measure of lawful protection.
- Patients deprived of freedom.
- Pregnant, nursing women.
- Participation in biomedical research within one month prior to inclusion.
Treatment and study plan
Primary outcomes
-
To evaluate the cutaneous lymphocytic infiltration
Time frame: 1 year
Secondary outcomes
-
Cutaneous infiltration T, B and Th17
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
University Hospital, Limoges
Other
Registry information
Acronym: NeuroSenSS
Important dates
- Study start
- 2012
- Primary completion
- 2016
- Study completion
- 2017
- First posted
- Nov 21, 2013
- Registry last updated
- Jan 11, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
NCT04078386
Primary Sjögren's Syndrome
Bengbu, Anhui, China
View Trial DetailsOpen-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
NCT06203457
Primary Sjögren's Syndrome
Ghent, Belgium
View Trial DetailsSafety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
NCT06484855
Primary Sjögren's Syndrome
Hefei, Anhui, China
View Trial DetailsA Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
NCT05817669
Primary Sjögren's Syndrome
Ghent, Belgium
View Trial Details